URGN
Urogen Pharma Ltd.
A biotech whose gel turns liquid to jelly at body heat, letting cancer drugs linger in the urinary tract for hours instead of minutes. Its FDA-approved treatments Jelmyto and Zusduri offer non-surgical options for rare bladder and kidney-tube cancers. Born in 2004 as Theracoat, it renamed itself UroGen in 2015 and won its first approval in 2020.
CINS: M96088105ISIN: IL0011407140HealthcareIL2 holders
Recent Activity
2026Q2
1 buy2 sells
-14.0K shares(-12.1%)
ARK InvestTRIM
-14.0K shares(-12.1%)
-14.0K shares(-12.1%)
-14.0K shares(-12.1%)
+29.6K shares
+29.6K shares
2026Q1
2 sells
-5.9K shares(-4.9%)
ARK InvestTRIM
-5.9K shares(-4.9%)
-7.3K shares(-6.0%)
-7.3K shares(-6.0%)
Loading more activity...